Bright Minds Biosciences (DRUG) Consolidated Net Income (2023 - 2024)

Bright Minds Biosciences' (DRUG) quarterly Consolidated Net Income came in at $35513.3 in Q4 2024, up 102.87% YoY from $17505.4 in Q1 2024, and down 78.87% on a QoQ basis from $168091.4 in Q2 2024.

Bright Minds Biosciences (DRUG) Consolidated Net Income (2023 - 2024) Analysis & Trends

Bright Minds Biosciences (DRUG) has 2 years of Consolidated Net Income data on file, last reported at $35513.3 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Consol Net Inc. (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 482.00 Mn
4 Revolution Medicines 43.64 Bn 43.64 Bn - -644.37 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 237.01 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 930.12
7 Royalty Pharma 33.72 Bn 35.84 Bn - 81.49 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 164.49 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -13.27 Mn
10 Bright Minds Biosciences 733.05 Mn 733.05 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 35,513.28
Jun 30, 2024 168,091.41
Dec 31, 2023 -1.24 Mn
Jun 30, 2023 -1.09 Mn